Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement

BATON ROUGE, LA  -- (Marketwired) -- 07/13/17 --  OncBioMune
Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"),
a revenue-stage biopharmaceutical company engaged in the development
of targeted cancer therapies, a proprietary cancer vaccine technology
and commercialization of a portfolio of products internationally, is
pleased to announce that the protocol for the planned Phase 2 trial
of ProscaVax for treatment-naïve prostate cancer patients is awaiting
approval from the Institutional Review Board (IRB) at the host
hospital, a preeminent North-eastern U.S. cancer research network.
The protocol was previously submitted to the U.S. Food and Drug
Administration and received no comments within the 30-day comment
period.

"The IRB review is the final approval necessary for us to begin the
first mid-stage trial of a therapeutic prostate cancer vaccine for
newly diagnosed patients that we are aware of," commented Andrew
Kucharchuk, President and Chief Financial Officer at OncBioMune. "We
are approaching a watershed moment for our company and the hundreds
of thousands of newly-diagnosed men suffering from the slow
progressing disease, We are eager to get the trial underway."

ProscaVax is an immunotherapeutic cancer vaccine consisting of a
combination of the tumor-associated antigen PSA (prostate specific
antigen) with the biological adjuvants interleukin-2 (IL-2) and
granulocyte-macrophage colony-stimulating factor (GM-CSF).

Per the protocol, ProscaVax will be evaluated for safety,
tolerability and efficacy as a novel therapy for patients at disease
presentation who, in collaboration with their oncologist, chose to
forego standard approved therapies, such as a radical prostatectomy,
radiation or brachytherapy, in favor of careful monitoring for
disease progression, a process known more commonly as "active
surveillance." Presently, there are no FDA-approved treatments for
prostate cancer patients in active surveillance.

As submitted, the Phase 2 clinical protocol will randomly enroll 120
early-stage prostate cancer patients with 40 patients on standard
active surveillance and 80 patients receiving ProscaVax. The
patients' PSAs and yearly biopsies will be monitored for disease
progression. The follow-up of the patients will be for two years. The
investigators are Dr. Rupal Bhatt, Dr. Glenn Bubley and Dr. David
Einstein at Beth Israel Deaconess Medical Center of Harvard Medical
School. Early clinical research of ProscaVax, including a Phase 1
study in PSA progressing prostate cancer in hormone-naïve and
hormone-independent patients, has shown ProscaVax to be well
tolerated with a strong safety profile. Data from late-stage patients
further shows signs of efficacy with respect to an increased immune
response and slowing tumor progression.

"We are very excited to move forward on a trial for patients on
Active Surveillance for prostate cancer. Immune therapies have shown
promise across many fields in oncology and we hope that ProscaVax™
can show activity in patients with low risk prostate cancer," said
Dr. Rupal Bhatt.

Sign up for OncBioMune email alerts at:
http://oncbiomune.com/email-alerts/. 

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical
company engaged the development of novel cancer immunotherapy
products, including a proprietary vaccine technology designed to
stimulate the immune system to attack tumor cells without damaging
healthy tissue. OncBioMune is also involved in drug development and
commercialization internationally through our wholly-owned
subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline
product, ProscaVax™, is scheduled to commence two, separate mid-stage
clinical trials in 2017: a Phase 2 for early-stage prostate cancer at
a major Northwest U.S. university cancer research hospital and a
Phase 2/3 study in Mexico for late-stage prostate cancer patients.
OncBioMune has a portfolio of targeted and licensed therapies, some
of which are biosimilars and generics to blockbuster drugs.
OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 that involve risks, uncertainties and assumptions
that could cause OncBioMune Pharmaceuticals' actual results and
experience to differ materially from anticipated results and
expectations expressed in these forward looking statements.
OncBioMune Pharmaceuticals has in some cases identified
forward-looking statements by using words such as "anticipates,"
"believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar
expressions. Among other factors that could cause actual results to
differ materially from those expressed in forward-looking statements
are OncBioMune Pharmaceuticals' need for, and the availability of,
substantial capital in the future to fund its operations and research
and development; the fact that OncBioMune Pharmaceutical's vaccines
and therapeutics may not successfully complete pre-clinical or
clinical testing, or be granted regulatory approval to be sold and
marketed in the United States or elsewhere. A more complete
description of these risk factors is included in OncBioMune
Pharmaceutical's filings with the Securities and Exchange Commission.
You should not place undue reliance on any forward-looking
statements. OncBioMune Pharmaceuticals undertakes no obligation to
release publicly the results of any revisions to any such
forward-looking statements that may be made to reflect events or
circumstances after the date of this press release or to reflect the
occurrence of unanticipated events, except as required by applicable
law or regulation.


Contact:
OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
akucharchuk@oncbiomune.com
Press spacebar to pause and continue. Press esc to stop.